Return to homepagePandemic Pact

CORONA - SARS-CoV-2-VLP-IVD - Development of a certified in vitro diagnostic (IVD) for the reliable determination of COVID-19-specific immune responses in human serum; subproject 1: Production and characterization of SARS-CoV-2-specific antibodies.

  • Funded by Federal Ministry of Research, Technology and Space (BMFTR)
  • Total publications:0 publications

Grant number: 03COV01A

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2020
    2021

  • Known Financial Commitments (USD)

    $144,598.18

  • Funder

    Federal Ministry of Research, Technology and Space (BMFTR)

  • Principal Investigator

    Katja Hanack

  • Research Location

    Germany

  • Lead Research Institution

    Universität Potsdam

  • Research Priority Alignment

    N/A

  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Diagnostics

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

In the SARS-CoV-2-VLP-IVD project, the partners will jointly establish a reliable and CE-certified diagnostic based on SARS-CoV-2 virus-like particles (VLPs) for the determination of human immune status. The Chair of Immunotechnology at the University of Potsdam will produce camelid antibody formats and provide the tools for affinity chromatographic purification. In addition, human antibodies will be produced that can be used as positive reference materials in the test system.